Nothing gets biopharma investors’ blood pumping quite like the rumor of a massive corporate marriage—especially when it involves two of the world’s most prominent drugmakers.

On Sunday, Bloomberg reported that the British drug giant AstraZeneca had approached California-based biotech Gilead about a potential M&A that would amount to “the biggest health care deal on record,” per the publication.

Read more .....